Actively Recruiting

Age: 18Years +
All Genders
ID04991922

BostonGene-Integrated Genomic Registry Study

Led by BostonGene · Updated on 2024-02-07

100000

Participants Needed

1

Research Sites

261 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to create a detailed database combining genetic, molecular, and clinical information from patients with various cancers. The goal is to identify genetic and molecular markers that could help improve future treatments and outcomes across different cancer types. The study recognizes that current research is limited by the lack of linked genetic and clinical data and seeks to address this gap through a comprehensive registry. Participants will have their clinical and pathological data collected, including detailed genetic information from their tumor biopsies. This data will be securely stored in an electronic registry. The study does not require additional scans or procedures; instead, it gathers existing diagnostic and treatment information. Follow-up data will be collected over time by contacting participants or their doctors periodically for up to 15 years. Throughout the study, researchers will review the associations between genetic findings and patient outcomes at intervals up to five years. They will also assess predictive probabilities and how patients may match to clinical trials. Participants can expect regular data collection about their cancer diagnosis, treatments, and outcomes without undergoing extra procedures, with their information securely maintained for long-term study.

CONDITIONS

Brief Title

BostonGene-Integrated Genomic Registry (BIGR)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Suspected or confirmed malignancy
  • Planned comprehensive genomic (> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing
  • Baseline demographics and treatment information available
  • Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment
  • Signed informed consent to participate in the study
  • Living in the United States at the time of enrollment
Not Eligible

You will not qualify if you...

  • Life expectancy less than 3 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person or remote)

Diagnostic Evaluation

Duration - Up to 1 month

Clinical and pathological information, including detailed genetic and molecular data from a participant's tumor biopsy, is collected and recorded.

1 visit (in-person or remote) to collect existing clinical and genomic data

Long-term Monitoring

Duration - Up to 15 years

Participants are followed over time with periodic collection of clinical outcomes and treatment information through contact with participants or their doctors.

Regular contact at specified intervals over 15 years (remote or in-person)

Trial Site Locations

Total: 1 location

1

BostonGene

Waltham, Massachusetts, United States, 02453

Actively Recruiting

Loading map...

Research Team

N

Nathan Fowler

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Assessment of the Impact of Reactive Oxygen Species from Rep...

Hyperbaric Oxygen

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates.

Manpreet Sambi, Leila Bagheri, Myron R Szewczuk

https://pubmed.ncbi.nlm.nih.gov/30941175